Sun Pharma, one of India's leading pharmaceutical companies, has finalized an agreement to acquire US-based Organon for $11.75 billion in cash, marking the largest deal in the Indian pharma sector to date. The acquisition, priced at $14 per share (a 24% premium), allows Sun Pharma to penetrate the US women's healthcare market and enhances its portfolio with biosimilar products. Following the acquisition, the combined annual revenue of both companies is projected to be $12.4 billion. Sun Pharma's CEO, Dilip Shanghvi, expressed excitement and anxiety about the deal, recalling the transformative acquisition of Ranbaxy in 2014. Analysts have raised concerns regarding Organon's $8.6 billion debt, but Sun Pharma plans to manage this through existing cash reserves and bank financing. The transaction is expected to close in early 2027, pending regulatory approvals. Industry leaders have praised the acquisition as a significant step for Indian pharmaceuticals on the global stage.